Karolinska Development’s portfolio company AnaCardio includes first patient in a phase 2a study of its drug candidate AC01
25 February 2025 - 7:10PM
UK Regulatory
Karolinska Development’s portfolio company AnaCardio includes first
patient in a phase 2a study of its drug candidate AC01
STOCKHOLM, SWEDEN February 25, 2025. Karolinska Development AB
(Nasdaq Stockholm: KDEV) today announces that its portfolio company
AnaCardio has dosed the first patient in the phase 2a part of the
GOAL-HF1 clinical study. The study will evaluate AnaCardio’s drug
candidate AC01 in patients with heart failure and reduced ejection
fraction. Study results from GOAL-HF1 are expected by the end of
the year.
AnaCardio AB is a privately held Swedish clinical-stage
biopharmaceutical company developing novel drugs to treat heart
failure. The company´s lead asset, AC01, is currently being
evaluated in a clinical phase 1b/2a study, GOAL-HF1, in patients
with heart failure and reduced ejection fraction (HFrEF).
The phase 2a part of the GOAL-HF1 study is randomized,
double-blind and placebo-controlled, aiming to evaluate the safety,
tolerability, pharmacokinetics and pharmacodynamics of AC01 in
patients with HFrEF following 28 days of treatment. The study is
being conducted at 13 highly specialized heart failure centers in
Sweden, the Netherlands, Italy and the UK.
”Following the promising results from the first part of the
phase 1b/2a study, we are pleased to see our portfolio company
AnaCardio advancing the clinical development of AC01 by initiating
the second part of the study,” says Viktor Drvota, CEO, Karolinska
Development.
Karolinska Development’s ownership interest in AnaCardio amounts
to 10%.
For further information, please contact:
Viktor Drvota, CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail:
viktor.drvota@karolinskadevelopment.com
Johan Dighed, General Counsel and Deputy CEO, Karolinska
Development AB
Phone: +46 70 207 48 26, e-mail:
johan.dighed@karolinskadevelopment.com
TO THE EDITORS
About Karolinska Development AB
Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life
sciences investment company. The company focuses on identifying
breakthrough medical innovations in the Nordic region that are
developed by entrepreneurs and leadership teams. The Company
invests in the creation and growth of companies that advance these
assets into commercial products that are designed to make a
difference to patients' lives while providing an attractive return
on investment to shareholders.
Karolinska Development has access to world-class medical
innovations at the Karolinska Institutet and other leading
universities and research institutes in the Nordic region. The
Company aims to build companies around scientists who are leaders
in their fields, supported by experienced management teams and
advisers, and co-funded by specialist international investors, to
provide the greatest chance of success.
Karolinska Development has a portfolio of eleven companies
targeting opportunities in innovative treatment for
life-threatening or serious debilitating diseases.
The Company is led by an entrepreneurial team of investment
professionals with a proven track record as company builders and
with access to a strong global network.
For more information, please visit
www.karolinskadevelopment.com.
Karolinska Development Ab (LSE:0P3C)
Historical Stock Chart
From Feb 2025 to Mar 2025
Karolinska Development Ab (LSE:0P3C)
Historical Stock Chart
From Mar 2024 to Mar 2025
